title: Speeding dating for docetaxel and recent debutantes in castration-resistant prostate cancer: 'plus or minus' may be a minus.
authors: Division of Cancer Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA.
authors: T B
authors: TB
authors: Dorff
authors: Division of Cancer Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA. Electronic address: diquinn@usc.edu.
authors: D I
authors: DI
authors: Quinn
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002369:Castration; D002986:Clinical Trials as Topic; D000077143:Docetaxel; D006801:Humans; D008297:Male; D058990:Molecular Targeted Therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D043823:Taxoids / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; C486839:intetumumab